Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04249258 · ClinicalTrials.gov registry record · Early Phase 1
Dobutamine on the Cardiac Conduction System
A Early Phase 1 study, sponsored by Northwell Health.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 37
- Enrollment target
NCT04249258 is a Early Phase 1 study that has completed, run by Northwell Health. The registered enrollment target is 37 participants.
The verdict
NCT04249258, a Early Phase 1 study, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
Our hypothesis is that Dobutamine will act in a similar fashion to Isoproterenol with respect to cardiac conduction. Our goal is to study the effects of Dobutamine on cardiac conduction and refractoriness during an Electrophysiology study (EPS). At the end of most EPS Isoproterenol is commonly administered in an effort to change the conduction properties of the heart. In our practice we have been using Dobutamine for this purpose for many years. Dobutamine has never been rigorously studied for this indication however. We designed this study to systematically study the effect of various doses of Dobutamine on the parameters of cardiac conduction and refractoriness that are commonly measured during an EPS. We are specifically looking to compare the effect that Dobutamine has on the sinus node with the effect it has on the atrioventricular node. Patients undergoing an EPS at Long Island Jewish Hospital will be recruited and consented. Measurements of various conduction parameters will be taken at baseline as is standard protocol for an EPS. Dobutamine will then be administered at doses of 5mcg/kg/min, 10mcg/kg/min, 15mcg/kg/min and 20mcg/kg/min. At each of these dosages the same conduction parameters will be measured. A comparison will then be made between the conduction parameters at baseline and when the Dobutamine is administered.
Interventions
- DRUG Dobutamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2020-01-14 |
| Est. Completion | 2021-11-20 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04249258
The ClinicalTrials.gov registry entry for NCT04249258 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dobutamine is the first listed.
NCT04249258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04249258 about?
NCT04249258 is a clinical study titled "Dobutamine on the Cardiac Conduction System". Our hypothesis is that Dobutamine will act in a similar fashion to Isoproterenol with respect to cardiac conduction. Our goal is to study the effects of Dobutamine on cardiac conduction and refractoriness during an Electrophysiology study (EPS). At the end of most EPS Isoproterenol is commonly admin...
What is the current status of trial NCT04249258?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 37 participants. The study started on 2020-01-14. Estimated completion is 2021-11-20.
What interventions are being tested in trial NCT04249258?
The interventions under investigation include: Dobutamine (DRUG).
Who is sponsoring clinical trial NCT04249258?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.